More on Sequenom (SQNM): Q1 misses on a per share basis as losses increase, but meets revenue...

|By:, SA News Editor

More on Sequenom (SQNM): Q1 misses on a per share basis as losses increase, but meets revenue estimates. Total sales jumped 158% over the prior year, led by continued growth in diagnostic sales. Total cost of revenues increased, primarily due to the significant increase in its test volumes and costs to support increased testing capacity. Shares +5% AH.